2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
Criscitiello C, Curigliano G, Burstein H, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? European Journal Of Surgical Oncology 2016, 42: 1780-1786. PMID: 27825710, DOI: 10.1016/j.ejso.2016.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsClinical Decision-MakingFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeHumansLymph Node ExcisionMastectomyMastectomy, SegmentalMedical OveruseNeoadjuvant TherapyPatient PreferenceSurgical OncologyConceptsBreast conservationNeoadjuvant therapyBreast cancerSystemic therapyPathologic complete response rateComplete response rateBreast conservation ratesEffective systemic treatmentPatient-level variablesInvasive surgical approachNeoadjuvant trialsInoperable patientsSurgical overtreatmentSystemic treatmentSurgical approachSurgical benefitsOncology communityResponse ratePatientsTherapyCancerAggressive optionsMastectomySurgeonsConservation rate
2013
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations